APAC's Role in Revamping Immunotherapeutics

The Asia-Pacific (APAC) region has emerged as an evolving center for immunotherapeutics, signifying a pivotal shift in the global landscape of advanced medical treatments.

Life Sciences Review | Monday, April 07, 2025

The Asia-Pacific (APAC) region has emerged as an evolving center for immunotherapeutics, signifying a pivotal shift in the global landscape of advanced medical treatments. Initially regarded as adopters of Western innovations, APAC nations increasingly contribute to the research, development, manufacturing, and clinical application of therapies that leverage the immune system to combat diseases—primarily cancer, autoimmune, and infectious diseases. This transformation is fueled by substantial investment, expanding research initiatives, enhanced clinical infrastructure, and a growing pool of scientific talent, positioning the region as a significant driver of future advancements in immunotherapy.

Market Expansion and Key Drivers

The immunotherapeutics market in APAC is experiencing substantial growth, including the rising prevalence of chronic diseases, particularly cancer, attributed to lifestyle changes, environmental influences, and aging populations. This increasing disease burden is creating a demand for more effective and less toxic treatment alternatives to conventional chemotherapy and radiation.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Simultaneously, rising healthcare expenditures—both public and private—are improving access to advanced therapies. Governments and healthcare systems across the region recognize the value proposition of immunotherapy, leading to increased funding for research, infrastructure development, and the gradual integration of these high-cost treatments into reimbursement frameworks, albeit at varying rates across different nations.

Advancements in diagnostic capabilities, particularly in molecular diagnostics and next-generation sequencing (NGS), play a critical role in patient stratification. They enable the identification of individuals most likely to benefit from specific immunotherapies based on biomarker profiles. This precision-driven approach enhances treatment efficacy and justifies the investment in these therapies. Additionally, increased awareness among patients and healthcare providers regarding the potential of immunotherapy is further driving its adoption.

Dominance and Diversification of Therapeutic Modalities

Monoclonal antibodies (mAbs), remarkably immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 pathways, represent the most established class of immunotherapeutics in APAC, aligning with global trends. These therapies have become standard-of-care treatments for multiple malignancies, including lung cancer, melanoma, and renal cell carcinoma. The region continues to witness extensive clinical trial activity involving checkpoint inhibitors as monotherapies and in combination regimens. Furthermore, the development of bispecific antibodies, which engage multiple targets simultaneously, is gaining momentum within regional research and development (R&D) pipelines.

Cellular therapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapy, have become a focal point of innovation in APAC. Several countries have approved CAR-T products for hematological malignancies, prompting substantial investment in specialized treatment centers equipped for the complex logistics of apheresis, cell engineering, conditioning regimens, and post-infusion monitoring. Research explores next-generation CAR-T therapies with improved safety profiles, efficacy against solid tumors, and allogeneic (off-the-shelf) platforms to enhance accessibility. Other cellular modalities, such as T-cell receptor (TCR)-engineered T cells and Natural Killer (NK) cell therapies, are also undergoing vigorous preclinical and early-phase clinical evaluation in the region.

Therapeutic vaccines, designed to stimulate immune responses against cancer-specific antigens, constitute another emerging area. However, compared to mAbs and CAR-T therapies, they remain in earlier stages of clinical validation. Research efforts are focused on identifying optimal antigen targets, developing innovative delivery platforms, and combining vaccines with checkpoint inhibitors to achieve synergistic effects.

Cytokine therapies, among the earliest forms of immunotherapy, continue to play a role. Newer formulations and combination approaches are being investigated to optimize therapeutic efficacy while minimizing adverse effects.

A Flourishing Research, Development, and Manufacturing Ecosystem

APAC is transitioning from a key immunotherapeutic market to a prominent innovation hub. Leading academic institutions and biotechnology clusters across the region generate groundbreaking insights in immunology and oncology, contributing significantly to the global R&D pipeline. Several clinical trials for immunotherapies are being conducted within APAC, including regional studies and global multi-center trials.

Investment in state-of-the-art R&D and manufacturing infrastructure is accelerating. The production of complex biologics, such as mAbs, requires advanced bioprocessing capabilities, while cell therapy manufacturing necessitates specialized Good Manufacturing Practice (GMP) facilities. Several APAC nations are expanding these capabilities to support clinical development and commercial supply, aiming to achieve greater regional self-sufficiency.

Strategic collaborations are also rising, linking academic research institutions, local biotech firms, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and global pharmaceutical companies. These partnerships leverage complementary expertise and resources, expediting the translation of scientific discoveries into viable therapeutic candidates.

Evolving Regulatory and Market Access Landscapes

Regulatory agencies across APAC are actively refining their frameworks to accommodate the complexities of immunotherapeutics, particularly cell and gene therapies. Many jurisdictions are streamlining approval processes, developing clear clinical development and manufacturing quality control guidelines, and implementing post-market surveillance protocols. While regulatory pathways vary across countries, there is a trend towards greater harmonization with international standards and participation in collaborative review initiatives.

Despite increasing regulatory approvals, patient access to immunotherapies remains contingent on reimbursement policies and healthcare infrastructure. Though coverage criteria and levels differ across markets, national health insurance schemes and alternative funding mechanisms progressively incorporate high-value immunotherapies. The logistical demands of therapies such as CAR-T, which require specialized treatment centers, further influence geographic accessibility.

Technological advancements are significantly enhancing the development and application of immunotherapeutics in APAC. AI and machine learning are employed in drug discovery, biomarker identification, and clinical trial optimization. Advanced bioinformatics and NGS are playing crucial roles in patient stratification, enabling the design of more personalized treatment approaches. Additionally, novel drug delivery systems are being explored to improve the precision and safety of immunotherapeutic agents.

The future of immunotherapeutics in APAC is expected to expand checkpoint inhibitors into earlier lines of therapy, the proliferation of combination strategies integrating immunotherapy with other treatment modalities, and significant advancements in cell therapy, including approvals for solid tumors and the evolution of allogeneic platforms. The increasing emphasis on personalized medicine, driven by sophisticated biomarker analysis, will refine treatment approaches. Additionally, the application of immunotherapeutics is likely to extend beyond oncology to address autoimmune and infectious diseases.

The immunotherapeutics sector in APAC is experiencing growth, increasing sophistication, and a surge in local innovation. Driven by urgent medical needs, rising investment, and scientific advancements, the region is transitioning from an adopter of immunotherapies to a key developer and manufacturer. While market conditions vary across nations, the overarching trajectory is one of rapid progress, promising transformative improvements in patient care and solidifying APAC's position as a pivotal contributor to the future of immunotherapy.

More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more

Specials

APAC's Role in Revamping Immunotherapeutics

The Asia-Pacific (APAC) region has emerged as an evolving center for immunotherapeutics, signifying a pivotal shift in the global landscape of advanced medical treatments.